See more : Hamelin Gold Limited (HMG.AX) Income Statement Analysis – Financial Results
Complete financial analysis of PaxMedica, Inc. Common Stock (PXMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PaxMedica, Inc. Common Stock, a leading company in the Biotechnology industry within the Healthcare sector.
- HannStar Board Corporation (5469.TW) Income Statement Analysis – Financial Results
- Miahona Co. (2084.SR) Income Statement Analysis – Financial Results
- Subaru Corporation (FUJHF) Income Statement Analysis – Financial Results
- FedEx Corporation (0QZX.L) Income Statement Analysis – Financial Results
- HOYA Resort Hotel Group (2736.TWO) Income Statement Analysis – Financial Results
PaxMedica, Inc. Common Stock (PXMD)
About PaxMedica, Inc. Common Stock
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomiasis. It is also involved in developing PAX-102, an intranasal formulation of suramin for neurologic indications. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York. PaxMedica, Inc. operates as a subsidiary of Tardimed Sciences LLC.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 3.91M | 1.79M | 2.22M | 936.78K | 484.11K |
| General & Administrative | 12.23B | 8.82M | 4.97M | 4.63M | 114.50K |
| Selling & Marketing | -12.22B | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 12.23M | 8.82M | 4.97M | 4.63M | 114.50K |
| Other Expenses | 0.00 | -5.51M | 173.35K | -53.54K | 0.00 |
| Operating Expenses | 16.15M | 10.60M | 7.20M | 5.57M | 598.61K |
| Cost & Expenses | 16.15M | 10.60M | 7.20M | 5.57M | 598.61K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 9.17K | 5.24K | 2.81M | 609.46K | 0.00 |
| Depreciation & Amortization | 167.90K | -5.90M | 173.35K | -53.54K | 171.86K |
| EBITDA | -16.15M | -10.60M | -7.20M | -5.62M | -598.61K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -16.15M | -10.60M | -7.20M | -5.57M | -598.61K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.14M | -4.20M | -3.03M | -2.26M | 0.00 |
| Income Before Tax | -18.29M | -14.80M | -10.23M | -7.83M | -598.61K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -167.90K | 4.19M | 2.81M | 663.00K | -171.86K |
| Net Income | -18.29M | -14.80M | -13.03M | -8.49M | -598.61K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -11.00 | -28.79 | -18.81 | -12.25 | -0.06 |
| EPS Diluted | -11.00 | -28.79 | -18.81 | -12.25 | -0.06 |
| Weighted Avg Shares Out | 1.66M | 514.22K | 692.91K | 692.91K | 10.02M |
| Weighted Avg Shares Out (Dil) | 1.66M | 514.22K | 692.91K | 692.91K | 10.02M |
PaxMedica Appoints David Hough M.D. as Chief Medical Officer
PaxMedica, Inc. Announces Second Quarter 2023 Financial Results and Business Update
PaxMedica to Join Fireside Chat with PCG Advisory Following Positive Top Line Results from PAX-HAT-301 Study
Why Is PaxMedica (PXMD) Stock Up Today?
PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301
PaxMedia hires ShareIntel to look into recent stock weakness, after a 45% plunge amid an 8-day losing streak
Best Penny Stocks To Buy? 3 Short Squeeze Stocks To Watch
Are Penny Stocks on Your February Watchlist? 3 Reasons to Buy
Deciding Which Penny Stocks to Buy? Use These 3 Tips
Why Is PaxMedica (PXMD) Stock Up Today?
Source: https://incomestatements.info
Category: Stock Reports